Multiple preclinical studies, including those in SCLC, breast, and colorectal cancers, demonstrate that SLFN11 loss can be overcome by targeting compensatory DDR pathways, particularly ATR, CHK1, and WEE1 (7, 56, 79, 80). This evidence concerns the gene SLFN11 and colorectal cancer.